DOCSLIB.ORG

Blockade of the Purinergic P2Y12 Receptor Greatly Increases the Platelet Inhibitory Actions of Nitric Oxide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Blockade of the Purinergic P2Y12 Receptor Greatly Increases the Platelet Inhibitory Actions of Nitric Oxide Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide Nicholas S. Kirkbya,b, Martina H. Lundberga, Melissa V. Chana, Ivana Vojnovica, Antonia B. Solomonb, Michael Emersonb, Jane A. Mitchellb,1, and Timothy D. Warnera,1,2 aThe William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, United Kingdom; and bNational Heart and Lung Institute, Imperial College London, London SW3 6LY, United Kingdom Edited by Marek Witold Radomski, Trinity College Dublin, Dublin, Ireland, and accepted by the Editorial Board July 31, 2013 (received for review November 1, 2012) Circulating platelets are constantly exposed to nitric oxide (NO) guanylyl cyclase, causing an increase in intraplatelet cGMP (13). released from the vascular endothelium. This NO acts to reduce Although this cGMP pathway is distinct from the cAMP pathway platelet reactivity, and in so doing blunts platelet aggregation and that is modulated by PGI2 and P2Y12, earlier studies have shown thrombus formation. For successful hemostasis, platelet activation that activation of these two inhibitory pathways produces a syn- and aggregation must occur at sites of vascular injury despite the ergistic antiplatelet effect (18). Further, it has been shown that constant presence of NO. As platelets aggregate, they release a NO donor drug can boost the effectiveness of P2Y12 inhibitors secondary mediators that drive further aggregation. Particularly against thrombus formation ex vivo (19, 20). Here we report that significant among these secondary mediators is ADP, which, acting treatment of platelets with P2Y12 receptor blockers dramatically increases the antiplatelet effects of NO, an increase that is very through platelet P2Y12 receptors, strongly amplifies aggregation. much greater than that already established for PGI2. This reveals Platelet P2Y12 receptors are the targets of very widely used anti- that activation of platelet P2Y12 receptors by ADP could provide thrombotic drugs such as clopidogrel, prasugrel, and ticagrelor. Here a common switching mechanism by which platelet sensitivity to we show that blockade of platelet P2Y12 receptors dramatically the antithrombotic effects of NO and PGI2 is rapidly reduced to enhances the antiplatelet potency of NO, causing a 1,000- to allow platelet activation, as required for hemostasis. It also raises 100,000-fold increase in inhibitory activity against platelet aggre- the important possibility that for individual patients, the effec- gation and release reactions in response to activation of receptors tiveness of P2Y12 receptor blockers may vary on the basis of their for either thrombin or collagen. This powerful synergism is ex- vascular production of NO and PGI2. This provides a rationale plained by blockade of a P2Y12 receptor-dependent, NO/cGMP- for the commonly reported disconnect between the results of ex insensitive phosphatidylinositol 3-kinase pathway of platelet acti- vivo testing of platelet responses and thrombotic outcomes. vation. These studies demonstrate that activation of the platelet Results and Discussion ADP receptor, P2Y12, severely blunts the inhibitory effects of NO. The powerful antithrombotic effects of P2Y12 receptor blockers P2Y12 Receptor Blockade Greatly Increases the Inhibition of Platelet may, in part, be mediated by profound potentiation of the effects Aggregation by NO. To study interactions between P2Y12 receptor of endogenous NO. activation and the inhibitory effect of NO on platelet aggregation, we used thrombin as the stimulus for platelet activation. Thrombin anti-platelet therapy | atherothrombosis | prostacyclin is a physiologically relevant agonist that provides a strong signal for ADP release. Similar to previous studies of this type (8), we found 1 U/mL thrombin to provide a maximal aggregation and secretion ctivation of platelets in a damaged blood vessel leads to response that was relatively insensitive to P2Y12 receptor blockade Aa well-characterized sequence of events, including the im- (Fig. S1). By using 1 U/mL thrombin as an agonist, we could portant release of secondary mediators of aggregation, notably – therefore study the effects of P2Y12 receptor blockade on re- ADP and thromboxane A2 (1 3). These mediators are the tar- sponses to NO without the confounding effects of a differing gets of antithrombotic drugs taken by many millions of patients baseline. In control conditions, the NO donor diethlyammonium as prophylactic protection against heart attacks and strokes. In (Z)-1-(N,N-diethylamino)diazen-1-ium-1,2-diolate (DEA/NONOate), particular, inhibition of thromboxane A2 production by aspirin which spontaneously releases NO at physiological pH (half-life ∼2 explains the antithrombotic utility of this drug, whereas blockade min), produced only weak inhibition of thrombin (1 U/mL)-induced of the ADP receptor, P2Y12, by drugs such as clopidogrel, pra- washed platelet aggregation, even at supraphysiological concen- sugrel, and ticagrelor provides a second, and possibly even trations (Fig. 1A). However, in the presence of the P2Y12 receptor stronger, antithrombotic protection (4). Within the circulation, blocker prasugrel active metabolite (PAM), both the potency and platelets are constantly exposed to antithrombotic mediators, the maximal effect of DEA/NONOate were dramatically in- A − ± notably prostaglandin I2 (PGI2), which is derived from the vas- creased (Fig. 1 ; logIC50 DEA/NONOate, 3.0 0.4; DEA/ cular endothelium, and nitric oxide (NO), which can be pro- NONOate +PAM, −7.9 ± 0.2; P < 0.0001; n = 8). This clearly duced by the vascular endothelium (5) and platelets themselves suggests a powerful interaction between NO and P2Y12 blockade. (6, 7). This leads to the understanding that there is an important interplay between endothelial-derived antiaggregatory mediators and platelet-derived proaggregatory mediators. For example, it Author contributions: N.S.K., M.H.L., J.A.M., and T.D.W. designed research; N.S.K., M.H.L., M.V.C., and I.V. performed research; A.B.S. and M.E. contributed new reagents/analytic has been demonstrated that activation of platelet P2Y12 recep- tools; N.S.K., M.H.L., M.V.C., and T.D.W. analyzed data; and N.S.K. and T.D.W. wrote tors by ADP causes inhibition of platelet adenylyl cyclase, which the paper. reduces the ability of PGI2 acting through prostaglandin IP re- Conflict of interest statement: T.D.W. has received consultancy fees from AstraZeneca and ceptors to elevate cAMP, and thus reduces platelet aggregation. Daichii Sankyo/Eli Lilly relating to clinical development of P2Y12 inhibitors. Hence, blockade of platelet P2Y12 receptors increases the sen- This article is a PNAS Direct Submission. M.W.R. is a guest editor invited by the sitivity of platelets to the antiaggregatory and antisecretory effects Editorial Board. of PGI2 (8, 9). This interaction is readily understandable, as both Freely available online through the PNAS open access option. 1 P2Y12 receptors and PGI2 have actions on a common signaling J.A.M. and T.D.W. contributed equally to this work. pathway, cAMP. 2To whom correspondence should be addressed. E-mail: [email protected]. Compared with PGI2, NO is less potent as an inhibitor of This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. platelet activation (10–17). NO acts by directly activating platelet 1073/pnas.1218880110/-/DCSupplemental. 15782–15787 | PNAS | September 24, 2013 | vol. 110 | no. 39 www.pnas.org/cgi/doi/10.1073/pnas.1218880110 Downloaded by guest on September 28, 2021 Vehicle DEA/NONOate PAM (3µM) DEA/NONOate Aggregation in washed A (1µM) +PAM platelets - -20 thrombinthrombin thrombinthrombin thrombinthrombin thrombinthrombin n i b 0 m o r 20 h t f o 40 n o Fig. 1. Blockade of the P2Y receptor sensitizes pla- i 60 12 t Light transmission i b i 80 Vehicle telets to the inhibitory effect of NO against thrombin- nh I Inhibition of thrombin- 100 PAM * induced aggregation, secretion, and Rap1 activation. induced aggregation (%) aggregation induced -12 -10 -8 -6 -4 -2 Thrombin (1 U/mL)-induced aggregation of washed 1 min platelets, determined by changes in light transmission, [DEA/NONOate] log (M) was only weakly inhibited by the NO donor, DEA/ A n = Aggregation in blood GPIIb/IIIa activation ADP+ATP secretion NONOate ( )( 8), but this effect was greatly in- B C D creased in platelets pretreated with the P2Y receptor -20 -20 -20 12 blocker PAM (3 μM). Traces show the effects of 1 μM 0 0 0 DEA/NONOate in the absence and presence of PAM. 20 20 20 40 40 40 Similarly, inhibition by DEA/NONOate of platelet ag- 60 60 60 gregation in hirudin-anticoagulated whole blood stim- (% inhibition)(% PAC-1 bindingPAC-1 μ + 80 Vehicle 80 Vehicle 80 ulated with SFLLRN-amide (10 M) AYPGKF-amide (30 Inhibition of PAR- Vehicle PAM μ B 100 PAM * 100 * Inhibition of thrombin- 100 PAM * M) and measured by impedance aggregometry ( ), induced aggregation (%) thrombin (1 U/mL)-induced GPIIb/IIIa activation by flow -12-10 -8 -6 -4 -2 -12 -10 -8 -6 -4 induced ATP+ADP release (%) -12 -10 -8 -6 -4 cytometry (C)andADP+ATP secretion, measured by [DEA/NONOate] log M [DEA/NONOate] log M [DEA/NONOate] log M amodified luminometric method (D), were also strongly potentiated by P2Y receptor blockade (n = 4 for each). Rap1 activation 12 E Thrombin (1 U/mL) also stimulated rapid activation of Rap1b-GTP 0.6 Vehicle Rap1, as determined by affinity purification of Rap1-GTP PAM * total Rap1b and Western blotting of lysates of platelets stimulated 0.4 under stirring conditions for 15 s (E). Rap1 activation was Thrombin (1U/ml) - + + + + + + + + - little altered by DEA/NONOate or P2Y12 receptor block- 0.2 (active / total) (active ade alone but was strongly inhibited by the combina- DEA/NONOate (uM) 0 0 0.01 1 100 0 0.01 1 100 - Rap1 activation tion. Platelet lysates incubated with GTPγS were included 0.0 Prasugrel-AM (3uM) -----++++- on blots as a positive control for affinity isolation of GTP S (pull-down control) - --------+ -10 -8 -6 -4 Rap1-GTP (n = 4 for each).
Load more

Recommended publications
  • Cox Inhibitors and Thromboregulation
    CLINICAL IMPLICATIONS OF BASIC RESEARCH Clinical Implications shown the importance of eicosanoids in preserving of Basic Research the dynamic balance among thrombosis, hemostasis, and the fluidity of blood. Recently, Cheng et al.1 presented compelling evi- dence that cell–cell interactions, principally between platelets and endothelial cells, that are mediated by ei- COX INHIBITORS cosanoids have a role in thrombosis. Using genetical- AND THROMBOREGULATION ly engineered mice that either overexpressed or lacked essential components of the eicosanoid pathway — ROM a historical perspective, there is perhaps no namely, receptors for prostacyclin (a platelet inhibitor Fmore interesting therapeutic saga than that of as- and vasodilator) or thromboxane A2 (a platelet agonist pirin, which began as a folk remedy, distilled from wil- and vasoconstrictor) — they found that the response low bark, and became a lifesaving preventive treatment of the intima of carotid vessels to mechanical injury is for ischemic cardiovascular disease. Aspirin primarily exuberant and leads to obstruction in mice lacking the inhibits the cyclooxygenase (COX)-dependent synthe- prostacyclin receptor. However, this response is muted sis of eicosanoids, which are the end products of me- in mice lacking the thromboxane A2 receptor or both tabolism of essential fatty acids and include prosta- receptors. In mice lacking the prostacyclin receptor cyclin and thromboxane A2. Numerous studies have (a defect that mimics the effects of COX-2–selective Endothelial cell Resting platelet Thromboxane A2 Soluble Stimulation CD39 Arachidonic acid Stimulated platelet COX inhibitor ATP and ADP Prostacyclin Nitric oxide AMP Carbon monoxide CD39 Resting platelet Figure 1. Effect on Platelet Reactivity of the Eicosanoids Thromboxane A2 and Prostacyclin, the Biologic Gases Nitric Oxide and Carbon Monoxide, and the Ectonucleotidase CD39.
    [Show full text]
  • Lysophosphatidic Acid and Its Receptors: Pharmacology and Therapeutic Potential in Atherosclerosis and Vascular Disease
    JPT-107404; No of Pages 13 Pharmacology & Therapeutics xxx (2019) xxx Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease Ying Zhou a, Peter J. Little a,b, Hang T. Ta a,c, Suowen Xu d, Danielle Kamato a,b,⁎ a School of Pharmacy, University of Queensland, Pharmacy Australia Centre of Excellence, Woolloongabba, QLD 4102, Australia b Department of Pharmacy, Xinhua College of Sun Yat-sen University, Tianhe District, Guangzhou 510520, China c Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, St Lucia, QLD 4072, Australia d Aab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA article info abstract Available online xxxx Lysophosphatidic acid (LPA) is a collective name for a set of bioactive lipid species. Via six widely distributed G protein-coupled receptors (GPCRs), LPA elicits a plethora of biological responses, contributing to inflammation, Keywords: thrombosis and atherosclerosis. There have recently been considerable advances in GPCR signaling especially Lysophosphatidic acid recognition of the extended role for GPCR transactivation of tyrosine and serine/threonine kinase growth factor G-protein coupled receptors receptors. This review covers LPA signaling pathways in the light of new information. The use of transgenic and Atherosclerosis gene knockout animals, gene manipulated cells, pharmacological LPA receptor agonists and antagonists have Gproteins fi β-arrestins provided many insights into the biological signi cance of LPA and individual LPA receptors in the progression Transactivation of atherosclerosis and vascular diseases.
    [Show full text]
  • NIH Public Access Author Manuscript Neuron Glia Biol
    NIH Public Access Author Manuscript Neuron Glia Biol. Author manuscript; available in PMC 2006 May 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Neuron Glia Biol. 2006 May ; 2(2): 125±138. Purinergic receptors activating rapid intracellular Ca2+ increases in microglia Alan R. Light1, Ying Wu2, Ronald W. Hughen1, and Peter B. Guthrie3 1 Department of Anesthesiology, University of Utah, Salt Lake City, UT, USA 2 Oral Biology Program, School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27510, USA 3 Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4142 Msc 7850, Bethesda, MD 20892-7850, USA Abstract We provide both molecular and pharmacological evidence that the metabotropic, purinergic, P2Y6, P2Y12 and P2Y13 receptors and the ionotropic P2X4 receptor contribute strongly to the rapid calcium response caused by ATP and its analogues in mouse microglia. Real-time PCR demonstrates that the most prevalent P2 receptor in microglia is P2Y6 followed, in order, by P2X4, P2Y12, and P2X7 = P2Y13. Only very small quantities of mRNA for P2Y1, P2Y2, P2Y4, P2Y14, P2X3 and P2X5 were found. Dose-response curves of the rapid calcium response gave a potency order of: 2MeSADP>ADP=UDP=IDP=UTP>ATP>BzATP, whereas A2P4 had little effect. Pertussis toxin partially blocked responses to 2MeSADP, ADP and UDP. The P2X4 antagonist suramin, but not PPADS, significantly blocked responses to ATP. These data indicate that P2Y6, P2Y12, P2Y13 and P2X receptors mediate much of the rapid calcium responses and shape changes in microglia to low concentrations of ATP, presumably at least partly because ATP is rapidly hydrolyzed to ADP.
    [Show full text]
  • Effect of Prostanoids on Human Platelet Function: an Overview
    International Journal of Molecular Sciences Review Effect of Prostanoids on Human Platelet Function: An Overview Steffen Braune, Jan-Heiner Küpper and Friedrich Jung * Institute of Biotechnology, Molecular Cell Biology, Brandenburg University of Technology, 01968 Senftenberg, Germany; steff[email protected] (S.B.); [email protected] (J.-H.K.) * Correspondence: [email protected] Received: 23 October 2020; Accepted: 23 November 2020; Published: 27 November 2020 Abstract: Prostanoids are bioactive lipid mediators and take part in many physiological and pathophysiological processes in practically every organ, tissue and cell, including the vascular, renal, gastrointestinal and reproductive systems. In this review, we focus on their influence on platelets, which are key elements in thrombosis and hemostasis. The function of platelets is influenced by mediators in the blood and the vascular wall. Activated platelets aggregate and release bioactive substances, thereby activating further neighbored platelets, which finally can lead to the formation of thrombi. Prostanoids regulate the function of blood platelets by both activating or inhibiting and so are involved in hemostasis. Each prostanoid has a unique activity profile and, thus, a specific profile of action. This article reviews the effects of the following prostanoids: prostaglandin-D2 (PGD2), prostaglandin-E1, -E2 and E3 (PGE1, PGE2, PGE3), prostaglandin F2α (PGF2α), prostacyclin (PGI2) and thromboxane-A2 (TXA2) on platelet activation and aggregation via their respective receptors. Keywords: prostacyclin; thromboxane; prostaglandin; platelets 1. Introduction Hemostasis is a complex process that requires the interplay of multiple physiological pathways. Cellular and molecular mechanisms interact to stop bleedings of injured blood vessels or to seal denuded sub-endothelium with localized clot formation (Figure1).
    [Show full text]
  • Activation of the Murine EP3 Receptor for PGE2 Inhibits Camp Production and Promotes Platelet Aggregation
    Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation Jean-Etienne Fabre, … , Thomas M. Coffman, Beverly H. Koller J Clin Invest. 2001;107(5):603-610. https://doi.org/10.1172/JCI10881. Article The importance of arachidonic acid metabolites (termed eicosanoids), particularly those derived from the COX-1 and COX-2 pathways (termed prostanoids), in platelet homeostasis has long been recognized. Thromboxane is a potent agonist, whereas prostacyclin is an inhibitor of platelet aggregation. In contrast, the effect of prostaglandin E2 (PGE2) on platelet aggregation varies significantly depending on its concentration. Low concentrations of PGE2 enhance platelet aggregation, whereas high PGE2 levels inhibit aggregation. The mechanism for this dual action of PGE2 is not clear. This study shows that among the four PGE2 receptors (EP1–EP4), activation of EP3 is sufficient to mediate the proaggregatory actions of low PGE2 concentration. In contrast, the prostacyclin receptor (IP) mediates the inhibitory effect of higher PGE2 concentrations. Furthermore, the relative activation of these two receptors, EP3 and IP, regulates the intracellular level of cAMP and in this way conditions the response of the platelet to aggregating agents. Consistent with these findings, loss of the EP3 receptor in a model of venous inflammation protects against formation of intravascular clots. Our results suggest that local production of PGE2 during an inflammatory process can modulate ensuing platelet responses. Find the latest version: https://jci.me/10881/pdf Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation Jean-Etienne Fabre,1 MyTrang Nguyen,1 Krairek Athirakul,2 Kenneth Coggins,1 John D.
    [Show full text]
  • Blood Platelet Adenosine Receptors As Potential Targets for Anti-Platelet Therapy
    International Journal of Molecular Sciences Review Blood Platelet Adenosine Receptors as Potential Targets for Anti-Platelet Therapy Nina Wolska and Marcin Rozalski * Department of Haemostasis and Haemostatic Disorders, Chair of Biomedical Science, Medical University of Lodz, 92-215 Lodz, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-504-836-536 Received: 30 September 2019; Accepted: 1 November 2019; Published: 3 November 2019 Abstract: Adenosine receptors are a subfamily of highly-conserved G-protein coupled receptors. They are found in the membranes of various human cells and play many physiological functions. Blood platelets express two (A2A and A2B) of the four known adenosine receptor subtypes (A1,A2A, A2B, and A3). Agonization of these receptors results in an enhanced intracellular cAMP and the inhibition of platelet activation and aggregation. Therefore, adenosine receptors A2A and A2B could be targets for anti-platelet therapy, especially under circumstances when classic therapy based on antagonizing the purinergic receptor P2Y12 is insufficient or problematic. Apart from adenosine, there is a group of synthetic, selective, longer-lasting agonists of A2A and A2B receptors reported in the literature. This group includes agonists with good selectivity for A2A or A2B receptors, as well as non-selective compounds that activate more than one type of adenosine receptor. Chemically, most A2A and A2B adenosine receptor agonists are adenosine analogues, with either adenine or ribose substituted by single or multiple foreign substituents. However, a group of non-adenosine derivative agonists has also been described. This review aims to systematically describe known agonists of A2A and A2B receptors and review the available literature data on their effects on platelet function.
    [Show full text]
  • Multi-Functionality of Proteins Involved in GPCR and G Protein Signaling: Making Sense of Structure–Function Continuum with In
    Cellular and Molecular Life Sciences (2019) 76:4461–4492 https://doi.org/10.1007/s00018-019-03276-1 Cellular andMolecular Life Sciences REVIEW Multi‑functionality of proteins involved in GPCR and G protein signaling: making sense of structure–function continuum with intrinsic disorder‑based proteoforms Alexander V. Fonin1 · April L. Darling2 · Irina M. Kuznetsova1 · Konstantin K. Turoverov1,3 · Vladimir N. Uversky2,4 Received: 5 August 2019 / Revised: 5 August 2019 / Accepted: 12 August 2019 / Published online: 19 August 2019 © Springer Nature Switzerland AG 2019 Abstract GPCR–G protein signaling system recognizes a multitude of extracellular ligands and triggers a variety of intracellular signal- ing cascades in response. In humans, this system includes more than 800 various GPCRs and a large set of heterotrimeric G proteins. Complexity of this system goes far beyond a multitude of pair-wise ligand–GPCR and GPCR–G protein interactions. In fact, one GPCR can recognize more than one extracellular signal and interact with more than one G protein. Furthermore, one ligand can activate more than one GPCR, and multiple GPCRs can couple to the same G protein. This defnes an intricate multifunctionality of this important signaling system. Here, we show that the multifunctionality of GPCR–G protein system represents an illustrative example of the protein structure–function continuum, where structures of the involved proteins represent a complex mosaic of diferently folded regions (foldons, non-foldons, unfoldons, semi-foldons, and inducible foldons). The functionality of resulting highly dynamic conformational ensembles is fne-tuned by various post-translational modifcations and alternative splicing, and such ensembles can undergo dramatic changes at interaction with their specifc partners.
    [Show full text]
  • Purinergic Receptors Brian F
    Chapter 21 Purinergic receptors Brian F. King and Geoffrey Burnstock 21.1 Introduction The term purinergic receptor (or purinoceptor) was first introduced to describe classes of membrane receptors that, when activated by either neurally released ATP (P2 purinoceptor) or its breakdown product adenosine (P1 purinoceptor), mediated relaxation of gut smooth muscle (Burnstock 1972, 1978). P2 purinoceptors were further divided into five broad phenotypes (P2X, P2Y, P2Z, P2U, and P2T) according to pharmacological profile and tissue distribution (Burnstock and Kennedy 1985; Gordon 1986; O’Connor et al. 1991; Dubyak 1991). Thereafter, they were reorganized into families of metabotropic ATP receptors (P2Y, P2U, and P2T) and ionotropic ATP receptors (P2X and P2Z) (Dubyak and El-Moatassim 1993), later redefined as extended P2Y and P2X families (Abbracchio and Burnstock 1994). In the early 1990s, cDNAs were isolated for three heptahelical proteins—called P2Y1, P2Y2, and P2Y3—with structural similarities to the rhodopsin GPCR template. At first, these three GPCRs were believed to correspond to the P2Y, P2U, and P2T receptors. However, the com- plexity of the P2Y receptor family was underestimated. At least 15, possibly 16, heptahelical proteins have been associated with the P2Y receptor family (King et al. 2001, see Table 21.1). Multiple expression of P2Y receptors is considered the norm in all tissues (Ralevic and Burnstock 1998) and mixtures of P2 purinoceptors have been reported in central neurones (Chessell et al. 1997) and glia (King et al. 1996). The situation is compounded by P2Y protein dimerization to generate receptor assemblies with subtly distinct pharmacological proper- ties from their constituent components (Filippov et al.
    [Show full text]
  • P2Y12-Dependent Modulation of ADP-Evoked Calcium Responses in Human Monocytes
    P2Y12-dependent modulation of ADP-evoked calcium responses in human monocytes Jonathon J. Micklewright A thesis submitted for the degree of Master of Science by Research University of East Anglia School of Biological Sciences February 2018 © This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with the author and that use of any information derived there from must be in accordance with current UK Copyright Law. In addition, any quotation or extract must include full attribution. Abstract The Gi-coupled, ADP-activated P2Y12 receptor is well-characterised as playing a key role in platelet activation via crosstalk with P2Y1. A crucial aspect of P2Y12-P2Y1 crosstalk in platelets involves ADP-induced intracellular calcium (Ca2+) mobilisation, however there is limited knowledge on the role of P2Y12 in ADP-evoked Ca2+ responses in other blood cells. Here, we investigate the expression of P2Y12 in human monocytes and the contribution of P2Y12 in THP-1 ADP-evoked Ca2+ responses. RT-PCR analysis showed that all ADP-binding P2Y receptors were expressed in THP-1 monocytes at the mRNA level, with P2Y12 expressed in CD14+ primary monocytes. P2Y12 protein was found to be expressed in THP-1 cells, using immunocytochemistry. ADP- evoked Ca2+ responses in fura-2-loaded THP-1 cells were completely abolished by a sarco/endoplasmic reticulum Ca2+-ATPase inhibitor, and by a phospholipase C inhibitor, indicating that these Ca2+ responses are mediated through GPCRs. Ca2+ responses induced by ADP were significantly reduced by the P2Y12 inhibitors ticagrelor and PSB- 0739 and by the P2Y6 antagonist MRS2578, but not by P2Y1 or P2Y13 inhibitors.
    [Show full text]
  • P2X and P2Y Receptors
    Tocris Scientific Review Series Tocri-lu-2945 P2X and P2Y Receptors Kenneth A. Jacobson Subtypes and Structures of P2 Receptor Molecular Recognition Section, Laboratory of Bioorganic Families Chemistry, National Institute of Diabetes and Digestive and The P2 receptors for extracellular nucleotides are widely Kidney Diseases, National Institutes of Health, Bethesda, distributed in the body and participate in regulation of nearly Maryland 20892, USA. E-mail: [email protected] every physiological process.1,2 Of particular interest are nucleotide Kenneth Jacobson serves as Chief of the Laboratory of Bioorganic receptors in the immune, inflammatory, cardiovascular, muscular, Chemistry and the Molecular Recognition Section at the National and central and peripheral nervous systems. The ubiquitous Institute of Diabetes and Digestive and Kidney Diseases, National signaling properties of extracellular nucleotides acting at two Institutes of Health in Bethesda, Maryland, USA. Dr. Jacobson is distinct families of P2 receptors – fast P2X ion channels and P2Y a medicinal chemist with interests in the structure and receptors (G-protein-coupled receptors) – are now well pharmacology of G-protein-coupled receptors, in particular recognized. These extracellular nucleotides are produced in receptors for adenosine and for purine and pyrimidine response to tissue stress and cell damage and in the processes nucleotides. of neurotransmitter release and channel formation. Their concentrations can vary dramatically depending on circumstances. Thus, the state of activation of these receptors can be highly dependent on the stress conditions or disease states affecting a given organ. The P2 receptors respond to various extracellular mono- and dinucleotides (Table 1). The P2X receptors are more structurally restrictive than P2Y receptors in agonist selectivity.
    [Show full text]
  • Role of the Serotonin Transporter and the 5-HT2A and 5-HT4 Receptors for Platelet Function in Blood
    Aus dem Institut für Prophylaxe und Epidemiologie der Kreislaufkrankheiten der Ludwig-Maximilians-Universität München Direktor: Prof. Dr. med. C. Weber Role of the serotonin transporter and the 5-HT2A and 5-HT4 receptors for platelet function in blood Dissertation zum Erwerb des Doktorgrades der Medizin an der Medizinischen Fakultät der Ludwig-Maximilians-Universität zu München Vorgelegt von Vasileios Bampalis aus Athen, Griechenland 2016 Mit Genehmigung der Medizinischen Fakultät der Universität München Berichterstatter: Prof. Dr. Med. Wolfgang Siess Mitberichterstatter: Priv. Doz. Dr. Dirk Sibbing Prof. Dr. Dr. Christian Sommerhof Dekan: Prof. Dr. med. dent. Reinhard Hickel Tag der mündlichen Prüfung: 28.01.2016 [i] Dedicated to my parents [ii] Contents Contents ........................................................................................................................ iii 1. State of the art ............................................................................................................ 1 1.1 Introduction: Serotonin, the happiness hormone .................................................. 1 1.2 Biosynthesis and degradation of 5-HT .................................................................... 2 1.3 5-HT transporter (SERT) and 5-HT receptors .......................................................... 4 1.4 Platelets and platelet function ............................................................................... 5 1.4.1 Platelet origin and morphology ......................................................................
    [Show full text]
  • Rare Platelet G Proteincoupled Receptor Variants: What Can We
    Rare platelet G protein-coupled receptor variants: What Can We Learn? 1 Header: (Platelet G protein-coupled receptor function) Article Authors: S. P. Nisar1, M L Jones2, M R Cunningham1, A D Mumford2 and S J Mundell1 on behalf of the UK GAPP Study Group 1School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD 2School of Cellular and Molecular Medicine, University of Bristol, Bristol. BS8 1TD. Footnote: Correspondence addressed to: Dr Stuart J Mundell, School of Physiology and Pharmacology University of Bristol, BS8 1TD, [email protected] This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bph.12941 Accepted This article is protected by copyright. All rights reserved. Summary Platelet expressed G protein-coupled receptors (GPCRs) are critical regulators of platelet function. Pharmacological blockade of these receptors forms a powerful therapeutic tool in the treatment and prevention of arterial thrombosis associated with coronary atherosclerosis and ischaemic stroke. However, anti-thrombotic drug therapy is associated with high inter-patient variability in therapeutic response and adverse bleeding side-effects. In order to optimise the use of existing antiplatelet drugs and to develop new therapies more detailed knowledge is required relating to the molecular mechanisms that regulate GPCR and therefore platelet function. One approach has been to identify rare, function-disrupting mutations within key platelet proteins in patients with bleeding disorders. In this review we describe how an integrated functional genomics strategy has contributed important structure-function information about platelet Article GPCRs with specific emphasis upon purinergic (P2Y12) and thromboxane (TP-α) receptors.
    [Show full text]